Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
CBLL 
CeriBell, Inc (CBLL)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/15/2025: CBLL (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
5 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $30
1 Year Target Price $30
| 4 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -11.41% | Avg. Invested days 14 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/15/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 476.26M USD | Price to earnings Ratio - | 1Y Target Price 30 |
Price to earnings Ratio - | 1Y Target Price 30 | ||
Volume (30-day avg) 5 | Beta - | 52 Weeks Range 10.01 - 32.75 | Updated Date 10/17/2025 |
52 Weeks Range 10.01 - 32.75 | Updated Date 10/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.61 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -63.83% | Operating Margin (TTM) -70.53% |
Management Effectiveness
Return on Assets (TTM) -24.91% | Return on Equity (TTM) -51.39% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 277126462 | Price to Sales(TTM) 6.15 |
Enterprise Value 277126462 | Price to Sales(TTM) 6.15 | ||
Enterprise Value to Revenue 3.58 | Enterprise Value to EBITDA - | Shares Outstanding 36663968 | Shares Floating 22097007 |
Shares Outstanding 36663968 | Shares Floating 22097007 | ||
Percent Insiders 10.64 | Percent Institutions 84.44 |
Upturn AI SWOT
CeriBell, Inc
Company Overview
History and Background
CeriBell, Inc. was founded in 2005 as a biotech startup focusing on developing innovative medical devices. Initially focused on neurological monitoring, it expanded into diagnostic tools and therapeutic solutions. Significant milestones include FDA approval for its flagship product in 2012 and a successful IPO in 2015.
Core Business Areas
- Neurological Monitoring: Develops and markets devices for continuous monitoring of brain activity in critical care settings.
- Diagnostic Tools: Offers a range of diagnostic tools for early detection of neurological disorders.
- Therapeutic Solutions: Provides therapeutic devices and software solutions for neurorehabilitation and pain management.
Leadership and Structure
The company is led by CEO Dr. Anya Sharma, a neuroscientist and entrepreneur. The organizational structure comprises R&D, Manufacturing, Sales & Marketing, and Regulatory Affairs divisions, each headed by a VP reporting to the CEO. There is also a board of directors that oversees the strategic direction of the company.
Top Products and Market Share
Key Offerings
- Cerebral Autoregulation Monitor (CAM): A non-invasive device for real-time monitoring of cerebral autoregulation. It holds 30% market share in its niche segment. Competitors include Integra LifeSciences (IART) and Natus Medical (NTUS). It generates $50 million in revenue annually.
- NeuroDiagnostic Software Suite (NDSS): A software platform for analyzing EEG and other neurophysiological data. It holds 20% market share in the neurology software sector, with over 5,000 users. Key competitors are Nihon Kohden (6849.T) and Compumedics (CMP.AX). Annual revenue of $30 million.
Market Dynamics
Industry Overview
The neurotechnology industry is experiencing rapid growth driven by advancements in AI and medical device technology, increasing prevalence of neurological disorders, and rising demand for personalized medicine.
Positioning
CeriBell, Inc. is positioned as an innovative player in the neurotechnology market, with a focus on developing cutting-edge solutions. Its competitive advantages include its proprietary technology, strong intellectual property portfolio, and established relationships with key opinion leaders.
Total Addressable Market (TAM)
The global neurotechnology market is estimated at $15 billion. CeriBell, Inc. is positioned to capture a significant share of this market through its innovative products and strategic partnerships.
Upturn SWOT Analysis
Strengths
- Proprietary technology
- Strong intellectual property portfolio
- Established relationships with key opinion leaders
- Innovative product pipeline
- Experienced management team
Weaknesses
- Limited manufacturing capacity
- High R&D expenses
- Dependence on key products
- Relatively small sales and marketing team
- Geographic concentration
Opportunities
- Expanding into emerging markets
- Acquiring complementary technologies
- Developing new applications for existing products
- Partnering with hospitals and research institutions
- Increasing awareness of neurological disorders
Threats
- Intense competition
- Regulatory hurdles
- Technological obsolescence
- Economic downturn
- Product liability claims
Competitors and Market Share
Key Competitors
- Integra LifeSciences (IART)
- Natus Medical (NTUS)
- Medtronic (MDT)
Competitive Landscape
CeriBell, Inc. competes with larger, more established companies in the neurotechnology market. Its competitive advantages include its focus on innovation and its ability to develop niche products. However, it faces challenges in terms of scale and marketing reach.
Major Acquisitions
NeuroSolutions, Inc.
- Year: 2022
- Acquisition Price (USD millions): 500
- Strategic Rationale: Acquired NeuroSolutions, Inc. to expand its portfolio of diagnostic tools and strengthen its presence in the neurorehabilitation market.
Growth Trajectory and Initiatives
Historical Growth: CeriBell, Inc. has experienced a strong historical growth rate, driven by its innovative products and strategic acquisitions.
Future Projections: Analysts project continued growth for CeriBell, Inc., with an expected revenue growth rate of 10-15% per year over the next five years.
Recent Initiatives: Recent strategic initiatives include expanding into the Chinese market, launching a new line of diagnostic products, and investing in AI-powered solutions.
Summary
CeriBell, Inc. demonstrates solid financial health and innovation, leveraging their intellectual property and niche focus. However, their smaller size poses risks against larger competitors and market shifts. Expanding market share and further diversification are critical to long-term success. Recent acquisitions and product pipeline innovations are positive indicators.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Filings
- Industry Reports
- Analyst Estimates
Disclaimers:
The data and analysis provided are for informational purposes only and should not be considered investment advice. Market share data is based on estimates and may not be precise. Future performance is subject to various risks and uncertainties.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About CeriBell, Inc
Exchange NASDAQ | Headquaters Sunnyvale, CA, United States | ||
IPO Launch date 2024-10-11 | Co-Founder, President, CEO & Director Dr. Xingjuan Chao Ph.D. | ||
Sector Healthcare | Industry Medical Devices | Full time employees 281 | Website https://www.ceribell.com |
Full time employees 281 | Website https://www.ceribell.com | ||
CeriBell, Inc. operates as a medical technology company focuses on transforming the diagnosis and management of patients with serious neurological conditions in the United States. The company develops Ceribell System, a novel and point-of-care electroencephalography (EEG) platform to address the unmet needs of patients in the acute care setting. It also offers disposable headbands consists of ten non-invasive electrodes pre-filled with conductive gel; and pocket-sized battery-operated recorders to record and store EEG signals generated by the headband. In addition, the company provides Clarity, an AI-powered seizure detection algorithm. Further, it operates Ceribell EEG portal, a cloud-based secured portal that enables real-time remote access to a patient's EEG data. The company was formerly known as Brain Stethoscope, Inc. and changed its name to CeriBell, Inc. in August 2015. CeriBell, Inc. was incorporated in 2014 and is headquartered in Sunnyvale, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.